Company intelligence / Profile preview

4100 Group

Lansing, Michigan, United Statesthe4100group.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

The 4100 Group is not a drug developer but an active venture capital/private equity investor focused on healthcare innovation. It provides long-term "patient capital" to startups and established firms developing new therapeutics, diagnostics, digital health solutions, and medical devices. Its investments span early-stage to growth/expansion rounds with a particular emphasis on tech-enabled care models and precision medicine. No direct clinical results apply to the group as it is not conducting trials itself but funds those who do.

Therapeutic areas: OphthalmologyInfectious Diseases
Industry: Investors

Beyond the preview

Go deeper on 4100 Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4100 Group.

Explore the full profile